Organic compounds

Lipocine To Present At The Ladenburg Thalmann Healthcare Conference

Retrieved on: 
Tuesday, July 6, 2021

SALT LAKE CITY, July 6, 2021 /PRNewswire/ --Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference.

Key Points: 
  • SALT LAKE CITY, July 6, 2021 /PRNewswire/ --Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference.
  • The webcast of this presentation will also be available on Lipocine's corporate website under "Events & Presentations" in the Investors section.
  • Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies.
  • TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing.

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

Retrieved on: 
Tuesday, July 6, 2021

Preclinical studies have shown that TTI-622 exhibits anti-tumor activity against AML cells as a monotherapy that is enhanced when combined with azacitidine or venetoclax.

Key Points: 
  • Preclinical studies have shown that TTI-622 exhibits anti-tumor activity against AML cells as a monotherapy that is enhanced when combined with azacitidine or venetoclax.
  • The dosing of this patient marks the second combination cohort that has been initiated with TTI-622, commented Dr. Ingmar Bruns, Trilliums Chief Medical Officer.
  • The combination of TTI-622 and azacitidine and venetoclax is being assessed as part of the ongoing, open-label study (NCT03530683).
  • Significant unmet medical need remains for elderly AML patients or those who are unfit for intensive chemotherapy, added Dr. Bruns.

TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule

Retrieved on: 
Tuesday, July 6, 2021

The trial is investigating the ability to expand the safety and efficacy of giredestrant as monotherapy and in combination with palbociclib into the early breast cancer setting.

Key Points: 
  • The trial is investigating the ability to expand the safety and efficacy of giredestrant as monotherapy and in combination with palbociclib into the early breast cancer setting.
  • The trial design evaluates the efficacy, safety, and pharmacokinetics of presurgical treatment with giredestrant plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with ER+ and HER2-negative untreated early breast cancer.
  • The scale of interest from patients further underlines the urgency to bring forward new treatment options to treat early stage breast cancer.
  • TRIO advances translational cancer research by introducing innovative and novel targeted therapeutic concepts into the clinical trial setting.

LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients

Retrieved on: 
Thursday, July 1, 2021

LG Chem announced topline results for the phase 2 study evaluating the efficacy and safety profiles of LC350189, a novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.

Key Points: 
  • LG Chem announced topline results for the phase 2 study evaluating the efficacy and safety profiles of LC350189, a novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.
  • LG Chem had received FDA clearance to commence a Phase 2 trial of LC350189 in June 2019 and conducted the Phase 2 study (CLUE study, NCT03934099) with 156 gout patients at 45 clinical sites in the US.
  • Many gout patients could benefit from medicines with improved efficacy and safety profiles from the current standard of care.
  • About LG Chem Life Sciences:
    LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally.

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer

Retrieved on: 
Thursday, July 1, 2021

HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.

Key Points: 
  • HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:
    As a single agent, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
  • Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension

Retrieved on: 
Thursday, July 1, 2021

London, UK, 1 July 2021 George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the worlds leading causes of death, today announces the initiation of two Phase III trials investigating its proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension.

Key Points: 
  • London, UK, 1 July 2021 George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the worlds leading causes of death, today announces the initiation of two Phase III trials investigating its proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension.
  • GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.
  • Fewer than one in five people with hypertension have the problem under control.3
    The Phase III trials follow successful earlier trials of a low dose triple combination which significantly outperformed traditional high blood pressure treatments without additional side effects.
  • Prof Dr Anthony Rodgers, Chief Scientific Officer of George Medicines, said: We are very pleased to be starting these two Phase III trials.

China Corn Products News Service - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 30, 2021

The "Corn Products China News" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Corn Products China News" newsletter has been added to ResearchAndMarkets.com's offering.
  • Corn Products China News provides you with real-time intelligence on China's corn products market.
  • China is the world's largest producer and exporter of many corn products, including citric acid, monosodium glutamate, vitamin C and vitamin B2.
  • Corn Products China News will help you stay ahead of the game in this fast-changing market with real-time reporting on the entire corn products industry chain, from grain markets to the downstream food and feed markets.

Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence

Retrieved on: 
Wednesday, June 30, 2021

The company presented results from a retrospective, observational study using data from the Veterans Health Administration (VHA) database, which includes healthcare encounters, treatments and laboratory tests at VHA facilities.

Key Points: 
  • The company presented results from a retrospective, observational study using data from the Veterans Health Administration (VHA) database, which includes healthcare encounters, treatments and laboratory tests at VHA facilities.
  • Details of the poster presentation at RSA are as follows:
    Poster #240: Treatment Patterns and Healthcare Resource Use Among Patients with Alcohol Dependence who Initiated Extended-Release Naltrexone: An Analysis of Veterans Affairs Data, was presented Sunday, June 20.
  • That study was one of the first studies to provide insights into the patient journey among veterans from alcohol dependence diagnosis to VIVITROL initiation and beyond.
  • Treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence

Retrieved on: 
Wednesday, June 30, 2021

The company presented results from a retrospective, observational study using data from the Veterans Health Administration (VHA) database, which includes healthcare encounters, treatments and laboratory tests at VHA facilities.

Key Points: 
  • The company presented results from a retrospective, observational study using data from the Veterans Health Administration (VHA) database, which includes healthcare encounters, treatments and laboratory tests at VHA facilities.
  • Details of the poster presentation at RSA are as follows:
    Poster #240: Treatment Patterns and Healthcare Resource Use Among Patients with Alcohol Dependence who Initiated Extended-Release Naltrexone: An Analysis of Veterans Affairs Data, was presented Sunday, June 20.
  • That study was one of the first studies to provide insights into the patient journey among veterans from alcohol dependence diagnosis to VIVITROL initiation and beyond.
  • Treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

CBDV Rebrands as DELIC Labs, Cementing Its Place in the DELIC Ecosystem

Retrieved on: 
Tuesday, June 29, 2021

DELIC Labs is a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development.

Key Points: 
  • DELIC Labs is a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development.
  • As part of the rebrand, DELIC Labs launched a new website, logo and branding to more accurately reflect its role within the DELIC platform.
  • DELIC Labs is applying for a Dealer's License, and intends to eventually commercialize its psilocybin research and associated intellectual property (IP).
  • The acquisition of DELIC Labs further establishes DELIC as a diversified psychedelics organization:The addition of DELIC Labs allows DELIC to add scientific-based research and analytics to its product offerings.